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Abstract 
Systemic lupus erythematosus (SLE) is a complex autoimmune disease 
where a loss of tolerance to nuclear antigens leads to inflammation in multiple 
organ systems. The cause of SLE remains ill defined, although it is known 
that a complex interplay between genes and environment is necessary for 
disease development. In recent years, case studies have reported that the 
incidence of SLE in the USA, for example, has increased by approximately 3 
fold. Although the reason for this is likely to be multifactorial, it has been 
hypothesized that the increasing incidence of autoimmune disease is due to 
considerable shifts in the bacterial communities resident the gut, collectively 
known as the gut microbiota, following a change in diet and the widespread 
introduction of antibiotics. Furthermore, a growing body of evidence suggests 
that the gut microbiota plays a role in the development of a range of 
autoimmune diseases including inflammatory bowel disease, multiple 
sclerosis, type one diabetes and rheumatoid arthritis. In this review, we 
summarize how advances in DNA-based sequencing technologies have been 
critical in providing baseline information concerning the gut microbiota in 
health and how variation amongst individuals in controlled by multiples factors 
including age, genetics, environment and the diet. We also discuss the 
importance of the gut microbiota in the development of a healthy immune 
system and how changes in particular bacterial phyla have been associated 
with immune abnormalities in animal models of autoimmune disease. Finally, 
in order to place the data in a clinical context, we highlight recent findings 
showing that abnormalities in the gut microbiota can be detected in patients 
with SLE, which provides the rationale for greater investigation into whether 
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microbiota-targeted therapies could be used for the treatment/prevention of 
disease. 
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Introduction 
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune 
disease, where a loss tolerance to nuclear antigens leads to pathology that 
can affect multiple organ systems. The diverse clinical presentations include 
rashes, arthritis, nephritis, seizures, serotosis, thrombocytopenia and 
psychosis [1]. Furthermore, progressive disability and systemic complication 
lead to high socioeconomic costs, with an unmet need for drugs that re-
establish immunological tolerance [1]. While the precise aetiology of SLE 
remains unknown, it is hypothesized that disease development is dependent 
upon a complex interplay between genetic predisposition and environmental 
factors (Figure 1). The identification of environmental factors that play a role in 
the development SLE may shed light on new therapeutic avenues for disease 
prevention/treatment, with growing evidence suggesting that one such factor 
may be the commensal bacteria that colonize the gastrointestinal tract [2,3]. 
In mammals trillions of commensal microbes, including bacteria, 
archaea, viruses and unicellular eukaryotes, collectively known as the 
microbiota, colonize the skin and mucosal surfaces. Whilst the role of viruses, 
archaea, and unicellular eukaryotes is relatively under studied, in recent years 
the bacterial components of the microbiota and its role in modulating immune 
responses has attracted intense investigation.  The largest community of 
commensal bacteria is located in the gastro-intestinal tract, thought to total as 
many as 1014 individual bacterium [4]. An intimate relationship between the 
host and the gut microbiota has developed following millions of years of co-
evolution, leading to a mutualistic relationship allowing for microbial survival, 
whilst preventing the colonization of pathogens [5]. Other contributions of the 
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gut microbiota to the host include help with metabolism of indigestible dietary 
components, protection against the colonisation of pathogenic bacteria, the 
production of certain vitamins, as well as the development of mature and 
diverse immune responses.  
The combined genomes of the gut microbiota, known collectively as 
the gut microbiome, are thought to contain 100-fold more genes than the 
human genome [6]. However, whilst the human genome is rarely modified by 
environmental factors, the gut microbiome is easily altered by infectious 
pathogens, antibiotic-treatment, diet, or other non-specific changes in 
environment, making it an attractive target for potential therapeutic 
intervention. Changes in the composition of the gut microbiota or changes to 
the abundance of certain phyla over others, generally defined as dysbiosis, 
have been implicated as a potential trigger for numerous disorders including 
systemic autoimmunity [4]. In order to understand how the gut microbiota can 
be targeted for therapy, first we must investigate the role of the commensal 
microflora during health and how this is altered by disease. In this review, we 
will discuss current knowledge concerning how changes in the composition of 
the gut microbiota may contribute to the onset of systemic autoimmunity in 
animal models and in humans. In addition, we will highlight novel findings 
describing the effect that environmental factors have on the stability of the gut 
microbiota and consequently to the immune system. A glossary of common 
terms used in the study of the gut microbiota can be found in Table 1. 
 
Study of the gut microbiota and gut microbiome 
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The development of DNA-based culture-independent methods has been 
fundamental for deepening our understanding of the bacterial species that 
constitute the gut microbiota. To date, the majority of studies investigating the 
taxonomic identity and function of the gut microbiota have used two DNA-
based sequencing methods. The first focuses on sequencing the 16S 
ribosomal RNA (rRNA) gene. The 16S rRNA gene contains sequences that 
are highly conserved amongst all bacteria that can be targeted by universal 
PCR primers [7]. It also contains hypervariable regions (V1 to V9) that display 
considerable sequence diversity and which can therefore be used to identify 
particular bacterial phylotypes [7]. 16S rRNA sequencing has been extremely 
useful for phylogeneic classification of particular species within the gut 
microbiota. However, analysis of the 16S rRNA gene alone does not provide 
any information about the functional capacity of the gut microbiome. The 
second widely-used technique, whole-genome shotgun next-generation 
sequencing (NGS), has been used to overcome this problem. Whole-genome 
shotgun sequencing analyzes every gene within a given sample, allowing 
functional profiles to be assigned to the gut microbiota based on the genes 
that are present, in a process also known as metagenomics. 
 Considering there is large inter-individual diversity in the gut microbiota, 
large-scale collaborative studies using NGS such as the European 
Metagenomics of the Human Intestinal Tract (MetaHIT) project [6] and the US 
Human gut microbiome Project (HMP) [8] have been instrumental in providing 
base-line information about microbial identify and functionality in the gut. We 
now know that although the gut microbiota is densely populated, there is 
relatively little phylogenetic diversity in the studied populations. Indeed, up to 
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90% of the intestinal gut microbiota is dominated by Firmicutes and 
Bacteroidetes [9], although the ratio of these phyla in a particular individual is 
highly variable [10]. Other phyla often found as minor constituents include 
Actinobacteria, Proteobacteria, Fusobacteria and Verrucomicrobia [10]. 
Despite the consistency of these main phyla between individuals, there is a 
considerable variation in their relative proportions and in the species present 
within each individual phylum. This suggests that it is highly unlikely that a 
core set of species form the gut microbiota in healthy individuals. It has been 
suggested that there are in fact three enterotypes of the gut microbiota, which 
can be identified based on changes in the levels of one of three genera, 
Prevotella, Bacteroides and Ruminococcus [11]. Despite the taxonomic 
diversity in the gut microbiota between individuals, the gut microbiome 
maintains a core functionality, which includes the genes necessary for 
carbohydrate and amino-acid metabolism [12]. Importantly, as many genes 
are only expressed under specific conditions, metagenome studies have 
started to be complemented with meta-transcriptomic and proteomic 
techniques, which will provide real-time information about gene expression 
and protein production by the bacteria in the gut.  
 
Factors that influence the gut microbiota 
 One of the current major challenges in the field of gut microbiota 
research is to try to understand the factors that influence its colonization and 
stability in healthy, and what causes dysbiosis in patients with SLE (Figure 2). 
Furthermore, we need to understand what causes variability in the gut 
 8 
microbiota between individuals, or in the same individual over time before we 
can even consider how manipulating the gut microbiota can be used to treat 
disease.  
Age 
Marked changes in the gut microbiota take place with age, with the greatest 
variability seen early and late in life. Following the initial colonisation event at 
birth, the communities of gastro-intestinal bacteria undergo compositional 
changes during the first three years of life to form a relatively stable gut 
microbiota during adulthood. During infancy, the gut microbiota is relatively 
unstable; there is greater variation amongst children than adults, albeit less 
diversity, and it is much more susceptible to environmental changes [13]. At 
birth, the sterile neonatal gastrointestinal tract is colonized by facultative 
aerobes, with bacteria appearing in the faeces within a few hours of birth [14]. 
Gradually consumption of oxygen by these bacteria changes the intestinal 
environment allowing the colonisation of strict anaerobes, which make up the 
majority of the adult gut microbiota [15]. Many outside factors can influence 
the colonisation event at birth, with one of the first major determinants being 
the mode of delivery (e.g. vaginal birth or caesarian section) [16]. Other 
factors that can affect the neonatal gut microbiota include the environment 
during birth (e.g. at home or in the hospital), prematurity, breastfeeding and 
antibiotic-treatment of the mother or baby [17]. Although recent studies have 
commented that changes to the gut microbiota during early-life cannot be 
detected in adulthood [18], it is has been suggested that this is a crucial 
developmental period or “window of opportunity” in which changes to the gut 
microbiota can have long-lasting effects on the immune system [19]. Indeed, 
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early-life antibiotic use has been identified as a predisposing risk factor for 
both peadiatric-onset inflammatory disorders such as Juvenile Idiopathic 
Arthritis (JIA) [20,21], type 1 diabetes [22] and asthma [23]. Understanding 
exactly how the colonisation event influences the development of the immune 
system may therefore be important for the prevention of systemic 
autoimmunity in both children and adults. 
 Similarly to infants, there is more microbial variation amongst elderly 
individuals. The most marked change in the gut microbiota of elderly 
individuals is an increase in the proportion of Bacteriodetes and a decrease of 
Firmicutes. However it is difficult to reach a definitive conclusion regarding the 
potential impact that this unbalance has on the immune system due to a high 
variation amongst different individuals [24]. Despite this, it has been 
suggested that a decrease in microbial diversity correlates with increased 
frailty and the levels of inflammatory markers during age [25]. As the world-
wide population ages and given the importance of age-related onset of 
autoimmunity, more information is needed to understand why/how the 
ecological make-up of the gut microbiota changes over time and how this 
impacts healthy aging.  
Genetics 
Similarities amongst familial pairs (e.g. mother-daughter, twin-pairs) indicate 
that gut microbiota may be influenced by genetics [26,27]. However, as there 
is similar co-variation amongst monozygotic and dizygotic twins, other factors 
are also likely to influence familial resemblances in the gut microbiota [27].  
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It is known that one genetic factor that influences the gut microbiota is sex. 
The gut microbiota of female and male mice is significantly different after 
puberty [28] and studies utilising non-obese diabetic (NOD) mice have shown 
that germ-free mice no longer display a gender-bias in disease development 
[28]. More recently, studies in humans have shown that changes to the gut 
microbiota associated with enthesitis-related arthritis (where inflammation 
occurs at the sites where tendons attach to bones) and obesity can be 
segregated based on sex [29,30]. Notably, as women are more likely to 
develop autoimmunity than men, it has been proposed that sex has a two-
step effect on autoimmune disease development, influencing both the 
production of hormones and colonization of microbes [28]. Other genetic 
factors may also influence the gut microbiota. For instance, HLA haplotype 
may support the growth of particular bacteria. One study has shown that the 
gut microbiota of HLA-transgenic mice expressing the rheumatoid arthritis 
(RA)-susceptible DRB1*0401 gene is not defined by age or sex when 
compared to HLA-transgenic mice expressing the RA-resistant DRB1*0402 
gene, but rather an increased abundance of Allobaculum Sp. [31]. More work 
is needed to understand how autoimmune disease risk-associated alleles and 
sex interact to affect the composition of the gut microbiota and the 
development of autoimmune disease.  
Environment 
Environmental factors that influence microbial diversity in the gut are 
extremely varied. Geographically defined populations can be segregated 
based on characteristic differences in the gut microbiota. For example, 
individuals living in the USA have a distinctly different faecal gut microbiota 
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compared to individuals living in Malawi or South America [15]. These 
changes in the gut microbiota are likely to be due to multiple factors including 
genetics and hygiene practices. However, dietary information collected from 
these cohorts indicates that whereas the diet of individuals living in Malawi 
and South America is rich in plant-derived polysaccharides, adults in the USA 
have a more protein-rich diet [15]. Two of the main genera of the gut 
microbiota used to segregate enterotype [11], namely Prevotella and 
Bacteroides seem to correlate with location and diet. Prevotella predominates 
in individuals who have a diet that is high in plant-derived polysaccharides or 
fibre, whilst Bacteroides is increased in diets rich in protein and saturated fats 
[32]. Direct evidence concerning the impact of the diet on the gut microbiota 
has also been collected; changing carbohydrate intake over four weeks leads 
to a profound and rapid change in the gut microbiota and its metabolic output 
[33,34,32]. Similarly to changes in enterotype, the incidence and prevalence 
of autoimmune disease varies based on geography, indicating that dietary 
differences and changes to hygiene practices that affect the gut microbiota 
may affect autoimmune disease development. Importantly, diet also directly 
influences the production of micronutrients produced by the gut microbiota. 
These products, such as short-chain fatty acids (SCFAs), and polyamines can 
directly influence host physiology (reviewed in [35]), which may in turn affect 
the development of autoimmunity. For example, SCFAs, such as butyrate, 
acetate and propionate, which are the end products of carbohydrate 
fermentation by the gut microbiota, support barrier function in the intestine by 
acting as a nutrient source for colonocytes [36] and can induce the 
differentiation of colonic [37] and peripheral Tregs [38]. 
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Gut microbiota and immune system – a reciprocal relationship 
In the healthy gut, the gut microbiota is constantly monitored by the mucosal 
immune system. Further to the physical barrier between the gut-epithelium 
and the bacteria in the lumen, formed by of a thick mucus layer, antimicrobial 
peptides, and secretory IgAs, lamina-propria resident macrophages and 
dendritic cells (DCs) survey the mucosal surfaces for unwanted or pathogenic 
bacteria [39]. Intestinal macrophages are involved in direct killing of bacteria 
via phagocytosis, whilst DCs, by presenting antigens to T and B cells, prime B 
and T cells to add another layer of protection at the mucosal surface [39]. In 
return, the gut microbiota directly affects the development of the immune 
system.  
Animal models have been critical for understanding how the gut 
microbiota influences immune system development. Germ-free mice, which 
are reared in a sterile environment and are devoid of commensal gut 
microbiota, have smaller isolated lymphoid follicles [40] and Peyer’s patches 
compared to specific-pathogen free (SPF) mice [41], as well as numerous 
deficiencies in the function and number of both lymphoid and myeloid-derived 
cells [41]. Perhaps the most striking differences between germ-free and SPF 
mice are the reduction of both the levels of secretory IgA and plasma cells in 
the intestine, demonstrating that commensal microbes are the driving force 
behind the development of the mucosal immune system [42]. T cell subsets in 
the gut are also abnormal in germ-free mice; there are reductions in T helper 
17 (Th17) cells in the lamina propria of the small intestine [43] and in Tregs in 
the colonic lamina propria [44]. Changes to the peripheral immune system are 
also observed in germ-free mice, in particular there is a reduction in serum 
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levels of IgG [45], perhaps due to fewer germinal centres in the spleen and 
mesenteric lymph nodes [46]. Mice in which the gut microbiota has been 
manipulated by antibiotic-treatment have also been used to provide important 
evidence concerning how the gut microbiota influences systemic immune 
homeostasis. For example, antibiotic-treatment of adult mice affects cytokine 
production by splenic macrophages, which has been associated with 
problems in the antiviral response to LCMV [47] and the differentiation of 
regulatory B cells [48].  Importantly, germ-free mice and antibiotic-treated 
mice have also been used to demonstrate that the gut microbiota directly 
influences the development of autoimmunity.  
 
Evidence that the gut microbiota influences systemic autoimmunity; 
lessons from animal models 
One of the first mouse models used to demonstrate that commensal bacteria 
influences peripheral autoimmunity was the K/BxN T cell receptor transgenic 
spontaneous mouse model of arthritis. K/BxN mice do not develop arthritis if 
housed in a germ-free environment, which is paralleled by a decrease in the 
production of autoantibodies, germinal centre formation, and Th17 cells 
compared to conventionally housed K/BxN (CNV) mice [49]. In this model, 
monocolonisation with segmentous filamentous bacteria (SFB) alone is 
sufficient to restore arthritis by inducing the differentiation of Th17 cells in the 
lamina propria, which can recirculate to the joint to cause arthritic 
inflammation [49]. It has also been reported that SFB-induced Th17 cells in 
the lamina propria can also recirculate to the brain causing inflammation in 
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experimental autoimmune encephalitis (EAE) [50]. Interestingly, 
monocolonisation with SFB has also been associated with the production of 
antinuclear antibodies in mice treated with LTR-Fc during and after gestation 
[51]. LTR-Fc treated mice do not develop normal secondary lymphoid organs, 
and a proportion spontaneously produces antinuclear antibodies in an IL-17-
dependent manner [51]. A caveat to this data is that no human equivalent of 
SFB has been identified making the clinical relevance of these studies unclear. 
Importantly, the gut microbiota does not only influence the differentiation of 
autoreactive T cells. In a spontaneous model of multiple sclerosis, 
demyelination is initiated in germ-free mice following colonisation with faeces 
isolated from SPF mice and is caused following entry of auto-antigen specific 
B cells into the germinal center of cervical lymph nodes [52]. In addition, we 
have recently demonstrated that changes to the gut microbiota caused by 
antibiotic-treatment or by changing the sterility of housing conditions reduces 
not only the severity of antigen-induced arthritis but also the differentiation of 
IL-10 producing regulatory B cells [48]. Alterations in the gut microbiota due to 
antibiotic-treatment or changes in housing environment led to a significant 
decrease in the production of IL-1 and IL-6, which in combination directly 
promote the differentiation of regulatory B cells [48]. 
In mouse models, a role for the intestinal gut microbiota in the 
development of SLE is less clear than for the development of arthritis and 
multiple sclerosis – the onset and severity of lupus-like disease is not 
profoundly altered in germ-free mice [53-55]. However, there is emerging 
evidence that there is dysbiosis and gut-pathology in many models of lupus. 
Female lupus-prone MRL/Mp-Faslpr (MRL/lpr) mice display changes in faecal 
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bacteria; there is an increase the family Lachnospiraceae and a decrease in 
Lactobacillaceae [56]. Notably, unlike many other disorders where a decrease 
in diversity has been associated with disease, MRL/lpr mice have increased 
microbial diversity in the faeces compared to non-disease controls [56]. In this 
study the authors observed that there were sex-related changes in the gut 
microbiota of lupus-prone mice compared to healthy mice; females were more 
likely to have an increase in Lachnospiraceae, which correlated with the 
development of more severe disease [56]. This observation is particularly 
relevant to human disease as women are approximately 10 times more likely 
to develop SLE that men. Another study also commented that gender-related 
differences could be observed in the gut of lupus-prone mice. Female SWR x 
NZBF1 (SNF1), which develop more severe nephritis than their male 
counterparts, have more plasma cells and 47-expressing T cells in the 
Peyer’s patches than male SNF1 mice [57]. Furthermore, analysis of RNA 
expression in the distal ileum showed that female SNF1 mice express much 
higher levels of pro-inflammatory mediators including IL-6, IL-9, IL-17, IL-22, 
IFN- and IFN- than male mice [57]. Although the gut microbiota was not 
analysed in this study, it does further support a role for the gut microbiota in 
lupus development and the gender bias of this disease. The important role of 
gut microbiota in driving a gender bias in autoimmunity more generally is 
supported by a study showing that diabetes in female mice can be 
suppressed by transferring gut microbiota from male mice into immature 
females [58]. 
Further evidence reinforcing a role for the gut microbiota in the 
development of lupus has been demonstrated by studies showing that dietary 
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manipulations can affect the severity and progression of disease. Feeding 
SNF1 mice acidified water (AW) delays the onset of nephritis compared to 
mice fed neutral water (NW); this is mirrored by a decrease in circulating anti-
nuclear antibodies and plasma cells [59]. AW-mice displayed gross 
differences in the gut microbiota compared to NW-mice, including a reduction 
in -diversity. Interestingly, in contrast to the K/BxN arthritis model, although 
the development of disease in NW-mice was associated with an increase in 
Th17 associated cytokines and genes in the distal ileum, no differences in 
SFB were observed [59]. This suggests that one bacterium alone is unlikely to 
drive autoimmunity but that multiple species may support Th17 differentiation.  
 
Evidence that the gut microbiota influences systemic autoimmunity; 
human sequencing studies.  
NGS-studies of human faeces have demonstrated that dysbiosis can be 
detected in several autoimmune diseases including rheumatoid arthritis 
[60,61], type 1 diabetes [22], multiple sclerosis [62] and inflammatory bowel 
disease [63]. Varying phenotypes have been described, including the 
observation that the gut microbiota in patients at disease onset, during 
chronicity, and following treatment is different [60,61]. This suggests that, 
while gut microbiota may alter disease development, inflammation and 
medication may both also affect the gut microbiota, a significant consideration 
when using enterotype to predict disease or when designing future 
therapeutic strategies.  
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Studies analyzing the gut microbiota in patients with SLE have only 
been carried out in the last couple years [2,3,64]. Initial studies have observed 
that there is a reduction in the ratio of Firmicutes to Bacteroidetes in the 
faeces of SLE patients compared to healthy controls [2]. Preliminary 
metagenome analysis has also been performed that demonstrates a shift in 
metabolic pathways in SLE, such as an overrepresentation of genes 
associated with glycan metabolism and oxidative phosphorylation [2]. The 
case for a metabolic shift in the gut microbiome of patients with SLE has been 
supported by another study where metabolomics was used to analyse faecal 
metabolites of SLE patients, revealing that there a deficiency in metabolites 
associated with pyrimidine, purine, and amino acid metabolism [3]. More 
recently, studies have started to try to understand whether changes in 
particular bacterial species in the gut are associated with particularly immune 
abnormalities observed in SLE, such as the increase in Th17 cells or natural 
IgM antibodies [64]. However, these studies remain purely correlative and 
further work is needed to understand exactly how the gut microbiota 
influences immune dysfunction in patients with SLE. Importantly, it is unlikely 
that only the bacterial components of our gut microbiome influence the 
development of SLE. The common “interferon alpha signature” in the 
peripheral blood of SLE patients suggests a potential viral trigger for disease 
development [65,66]. The human body is inhabited by a multitude of viruses, 
known as the virome, which can have a direct influence on the host and the 
gut microbiome. To date, there is little information analyzing how the virome 
may contribute to the development of autoimmunity. However, analysis of the 
virome as a potential trigger for SLE represents an exciting novel avenue that 
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will hopefully be explored in future research. A summary of key findings 
supporting a role for dysbiosis in the development of SLE can be found in 
Table 2. 
 
Possible therapeutic strategies for modulation of the gut microbiota 
The ultimate goal of therapies targeting the gut microbiota is to facilitate 
health by supporting the growth of anti-inflammatory commensal bacteria 
whilst eliminating potential pathobionts. At present, proposed therapeutic 
strategies can be divided into two broad categories (Figure 3). The first 
approach involves direct elimination or modification of the gut microbiota 
through antibiotics treatment or faecal transplant. Whilst targeted antibiotic 
strategies have been successfully used to treat disorders associated with a 
known pathobiont, such as peptic ulcers caused by Helicobacter pylori [67], 
limitations of the use of antibiotics for the treatment of autoimmune disease 
are caused by the lack of a known pathogen. Thus, the long-term use of 
broad-spectrum antibiotics that could be currently used for therapy may lead 
to the depletion of both pathogenic and beneficial bacteria, and lead to an 
increase in antibiotic resistance. Notably, animal studies have also shown that 
whilst treatment with antibiotics suppresses inflammation, it can also lead to 
reduction in regulatory populations of cells, suggesting that non-specific 
elimination of the gut microbiota perturbs immune homeostasis [48].  
Interestingly, treatment of RA patients with minocycline, a tetracycline-derived 
antibiotic, is efficacious in reducing symptoms [68]. However, the anti-
rheumatic activity of minocycline is currently attributed to its ability to inhibit 
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matrix metalloproteinases, not it’s broad-spectrum antibiotic activity [69]. 
Importantly, minocycline has a high toxicity profile, leading to gastro-intestinal 
problems [68], and adverse reactions include the development of lupus-like 
disease [70,71]. 
Restoring microbial health by transplanting a foreign gut microbiota may 
represent a more attractive treatment option than antibiotic centric therapies, 
and faecal transplant has been very effectively used to treat recurrent 
Clostridium difficile infections. There are also case reports showing promising 
results for faecal transplant in the inflammatory bowel diseases, with one 
publication describing complete remission in patients with refractory ulcerative 
colitis up to 13 years later following fecal transplant [72]. There have even 
been studies describing an improvement in the neurological symptoms of 
three multiple sclerosis patients [73] after being administered faecal 
transplants for chronic constipation, and in a child with myoclonus dystonia 
following faecal transplant for chronic diarrhea [74]. More work is needed to 
understand whether this treatment will work for other disorders such as lupus. 
Indeed, the best approach may be a short course of antibiotics followed by a 
faecal transplant from a healthy donor. 
The second therapeutic approach involves dietary modification by the use of 
prebiotics/probiotics to support the growth of immune-regulatory bacteria. 
Probiotics consist of live cultures of bacteria that confer beneficial effects to 
the host when properly administered. Probiotics strains that have been 
identified include Bifidobacteria, Lactobacilli and Streptococci. For example, 
administration of Lactobacillus casei has been shown to improve the 
symptoms of diabetes in KK-Ay diabetic mice [75], although these data are 
 20 
yet to be translated to humans. Interestingly, the idea of administering 
beneficial bacteria in the diet is not a new concept. There are papers from the 
early nineteen hundreds describing an improvement in autoimmune arthritis 
after patients ingested sterilized milk supplemented with live cultures of 
Streptococcus lacticus and Bacillus bulgaricus [76]. Prebiotics are non-
digestible substances that may improve host health by promoting the growth 
of probiotic gut bacteria. Fructo-oligosaccharides and inulin are amongst the 
prebiotic compounds that are thought to promote bacteria such as 
Bifidobacteria and Lactobacilli [77]. Of note, inulin and fructo-oligosaccharides 
are broken down into short-chain fatty acids, which have been shown to 
promote the differentiation of Tregs [37,38], and improve barrier function in 
the gut [36]. Both prebiotics and probiotics have been shown to prevent 
antibiotic-induced diarrhea or food allergies [78].  Importantly, this represents 
a non-invasive treatment for suppression of autoimmunity. However, more 
studies in animals and in humans are needed to understand the best way to 
manipulate the gut microbiota to suppress inflammation and restore health. In 
addition, the composition of gut microbiota may also be viewed as a risk factor 
for disease development, like smoking for instance, and will therefore be 
important in predicting disease development/progression. 
 
Conclusions 
Over the last decade, much progress has been made in understanding of how 
the gut microbiota during health and disease. It is now know that the gut 
microbiota is a dynamic “forgotten organ”, which affects host physiology at 
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both mucosal sites and peripheral sites. Advancements in sequencing 
technologies have been critical for the increase in information concerning gut 
microbiota stability during health in humans, whilst animal models have 
provided mechanistic information concerning exactly how the gut microbiota 
influences host immunity. More information is needed to understand how the 
gut microbiota interacts with host genetics to cause autoimmune disease.  
Prospective studies are now necessary to establish causation of the gut 
microbiota in the development of autoimmunity, as well as a greater 
understanding of how current therapeutics change the gut microbiota, which is 
likely to inform whether an “autoimmune” gut microbiota can be manipulated 
to restore microbial health. In conclusion, greater understanding into the 
diverse contributions of the gut microbiota to systemic autoimmunity will open 
new possibilities for diagnostic, preventative, and therapeutic approaches.  
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Term Meaning 
Dysbiosis  Microbial imbalance on or inside of the host 
Enterotype A way to stratify individuals based on their gut 
microbiota 
Metabolomics The study of the metabolites found within a given 
environmental sample 
Metagenomics The study of the genetic material within a given 
environmental given sample 
Metatrascriptomics The study of the function and activity of 
transcripts found within a given environmental 
sample 
Microbiome The collective genomes of the microorganisms 
found on the host 
Microbiota The ecological community of microorganisms that 
live on the host 
Pathobiont A commensal bacteria that has the potential to 
cause pathology 
Prebiotic A non-digestible food ingredient that promotes 
the growth of beneficial bacteria 
Probiotic A dietary supplement containing live beneficial 
bacteria 
Proteomics The study of proteins found within a given 
environmental sample 
Virome The collection of viruses on the host 
-diversity The ratio between local and regional diversity 
Table 1. A glossary of terms commonly used in the study of the gut microbiota 
and gut microbiome. 
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Year Experimental system Findings Ref 
2014 MRL-lpr mice 
Readout: disease severity, 
analysis of stool by 16S 
rRNA sequencing 
Faecal samples from female mice with 
severe lupus-like disease have an 
increase in Lachnospiraceae compared 
to samples from male mice with mild 
disease 
[56] 
2015 SNF1 mice 
Readout: disease severity, 
analysis of stool by 16S 
rRNA sequencing 
Feeding mice acidified water delays 
onset of lupus-like disease; delayed 
disease onset associated with decrease 
in -diversity of faecal bacteria compared 
to control mice 
[59] 
2015 SLE patients  
Readouts: analysis of stool 
by 16S rRNA sequencing 
Lower Firmicutes/Bacteriodetes ratio in 
stool of SLE patients compared to 
healthy controls 
[2] 
2015 SLE patients; 
Readout: analysis of stool 
by liquid chromatography 
and mass spectrometry 
Reduction in metabolites associated with 
purine, pyrimidine and amino acid 
metabolism in faecal samples from SLE 
patients compared to healthy controls. 
 
[3] 
Table 2. Summary of key findings supporting a role for dysbiosis in the 
development of SLE. 
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Figure legends 
Figure 1. Development of autoimmune disease is dependent upon a 
complex interplay between genetic and environmental factors.  
Although the exact aetiopathogenesis of autoimmune disease remains 
unknown, it is hypothesized that a combination of both genetic and 
environmental factors are needed for disease development. The relative 
importance of genetics versus environmental factors in the development of 
autoimmunity is yet to be understood, although it is currently under active 
investigation. Although several environmental factors have been linked to 
disease development in genetically predisposed individuals, recent research 
has suggested that changes in the composition of the gut microbiota may play 
an important role.  
 
Figure 2. Proposed causes of dysbiosis.  
Pathological changes in the gut-microbiota, or dysbiosis, has been implicated 
as a potential risk factor for the development of autoimmune diseases such as 
SLE. Many factors could contribute to dysbiosis, including host-genetics, age, 
diet and other environmental factors. Genetic factors that have been 
associated with changes in the microbiota include sex and certain disease 
associated risk alleles such as HLA haplotype. Changes with age have also 
been associated with immune pathology, such as changes to microbial 
exposure at birth or due to aging. Environmental factors that may cause 
dysbiosis and have also been associated with increasing incidences in 
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autoimmune disease include a so-called “western diet” which is high in fat and 
protein, and the widespread introduction of antibiotics.  
 
Figure 3. Proposed microbiota-targeted therapies. 
Proposed microbiota targeted therapies can be split into two categories: a) 
Direct targeting of the microbiota by administration of selective antibiotics, 
which aim to target known pathobionts, or faecal transplant, where microbiota 
from healthy individuals is transferred into an individual with dysbiosis. b) 
Altering diet regime (i.e. from high fat to plant based), administration of 
prebiotic and/or pro-biotics; these will directly/indirectly change the 
composition of the gut microbiota and their metabolic product. All therapies 
aim to restore microbial health in individuals with dysbiosis to treat 
inflammation. 
